NCT03927690 - Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 24, 2019

Primary Completion Date

June 17, 2022

Study Completion Date

August 31, 2022

Conditions

Diabetic Macular Edema

Interventions

DRUG

LKA651

LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase

DRUG

Lucentis

Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase

Trial Locations (22)

13353

Novartis Investigative Site, Berlin

14012

Novartis Investigative Site, Córdoba

30625

Novartis Investigative Site, Hanover

33143

Novartis Investigative Site, Miami

37075

Novartis Investigative Site, Göttingen

41009

Novartis Investigative Site, Seville

41380

Novartis Investigative Site, Kocaeli

48145

Novartis Investigative Site, Münster

50009

Novartis Investigative Site, Zaragoza

72076

Novartis Investigative Site, Tübingen

78240

Novartis Investigative Site, San Antonio

78750

Novartis Investigative Site, Austin

90211

Novartis Investigative Site, Beverly Hills

95670

Novartis Investigative Site, Rancho Cordova

96701

Novartis Investigative Site, ‘Aiea

02118

Novartis Investigative Site, Boston

00612

Novartis Investigative Site, Arecibo

08190

Novartis Investigative Site, Sant Cugat del Vallès

08025

Novartis Investigative Site, Barcelona

06100

Novartis Investigative Site, Ankara

06490

Novartis Investigative Site, Ankara

06500

Novartis Investigative Site, Ankara